| P50 | author | Jacques F. Meis | Q51269909 |
| | Willem Melchers | Q56859383 |
| | Paul E. Verweij | Q70514014 |
| | Roger J Brüggemann | Q88523388 |
| | Seyedmojtaba Seyedmousavi | Q40062294 |
| | Johan Mouton | Q42711138 |
| P2860 | cites work | Emergence of azole-resistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health | Q26999421 |
| | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| | Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 |
| | Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism | Q30853962 |
| | Side population cells and Bcrp1 expression in lung. | Q33186312 |
| | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. | Q33613758 |
| | Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates | Q34041500 |
| | Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis | Q34290034 |
| | Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy | Q34754956 |
| | Aspergillosis. Pathogenesis, clinical manifestations, and therapy | Q35038459 |
| | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba | Q43111743 |
| | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing | Q43153444 |
| | Azole-resistant Aspergillus fumigatus, Iran. | Q43171569 |
| | Azole resistance in Aspergillus: a growing public health menace | Q43607400 |
| | Multidrug resistance in Aspergillus fumigatus. | Q44261807 |
| | Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. | Q44318186 |
| | Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus | Q45034615 |
| | Quantitative assessment of epithelial lining fluid in the lung | Q45698958 |
| | Azole-resistant central nervous system aspergillosis. | Q46094844 |
| | Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia | Q46487039 |
| | Activity of BAL 4815 against filamentous fungi | Q46713703 |
| | In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. | Q46801074 |
| | Bronchoalveolar lavage. Quantitation of intraalveolar fluid? | Q50786468 |
| | In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. | Q51037587 |
| | Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. | Q54342323 |
| | Multi-azole resistance in Aspergillus fumigatus | Q56837308 |
| | Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis | Q56993324 |
| | Aspergillosis—and a misleading sensitivity result | Q63914856 |
| | Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution | Q68861405 |
| | Invasive aspergillosis in critically ill patients without malignancy | Q80269940 |
| | Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection | Q83453027 |
| | Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. | Q35848799 |
| | Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. | Q36505281 |
| | In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. | Q36558484 |
| | Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis | Q36757621 |
| | Interpretation of antibiotic concentration ratios measured in epithelial lining fluid | Q36936597 |
| | New and emerging treatments for fungal infections | Q37026459 |
| | Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 |
| | Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates | Q37263430 |
| | Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model | Q37263435 |
| | In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole. | Q37263445 |
| | Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei | Q37291463 |
| | Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. | Q37335649 |
| | Azole-resistance in Aspergillus: proposed nomenclature and breakpoints | Q37625111 |
| | Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens. | Q37713035 |
| | Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. | Q37762760 |
| | Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. | Q37926156 |
| | Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents | Q37927017 |
| | Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections | Q38005226 |
| | Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections | Q38159688 |
| | Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms | Q38222570 |
| | Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases | Q38285488 |
| | Therapeutic outcome in invasive aspergillosis | Q38970340 |
| | Isavuconazole therapy protects immunosuppressed mice from mucormycosis | Q39684037 |
| | Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. | Q40274784 |
| | Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. | Q41771784 |
| | In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species | Q42078338 |
| | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species | Q42084568 |
| | Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. | Q42206937 |
| | Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h | Q42262837 |
| | First reported case of azole-resistant aspergillus fumigatus due to the TR/L98H mutation in Germany | Q42383280 |
| | Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure | Q42555868 |
| | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect | Q42577557 |
| | In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. | Q42726676 |
| | Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers | Q43094166 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Aspergillus fumigatus | Q134359 |
| | pharmacodynamics | Q725307 |
| | isavuconazole | Q6079042 |
| | isavuconazonium sulfate | Q27158829 |
| P304 | page(s) | 2855-2866 | |
| P577 | publication date | 2015-03-09 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model | |
| P478 | volume | 59 | |